ArticleJournal of immunology research2026
Identification and Analysis of Biomarkers Associated With Lipid Metabolism and Ferroptosis in Ulcerative Colitis.
Article in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification and Analysis of Biomarkers Associated With Lipid Metabolism and Ferroptosis in Ulcerative Colitis.Journal of immunology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundMounting evidence shows that lipid metabolism and ferroptosis contribute to ulcerative colitis (UC), but the mechanism remains unclear. This study aimed to identify related biomarkers, clarify their roles in UC, and provide insights into optimized therapies.
methodsUC transcriptome, lipid metabolism, and ferroptosis-related gene (FRG) data were analyzed. Biomarkers were screened via differential expression analysis, consensus clustering, Venn, and machine learning, with expression validation. Receiver operating curve (ROC) analysis assessed predictive efficacy; functional enrichment, molecular regulatory, and immune infiltration analyses were performed. Real-time PCR verified candidate biomarkers in clinical samples.
resultsTwo biomarkers (acyl-CoA synthetase ligases 4 [ACSL4] and prostaglandin-endoperoxide synthase 2 [PTGS2]) were identified that distinguished UC from control samples. They may involve hematopoietic cell lines, cytokine-cytokine receptor interaction, and MALAT1 binding hsa-miR-576-5p/hsa-miR-503-5p. Notably, 27 differentially infiltrated immune cells were found (p < 0.05), with CD56dim natural killer cells negatively correlating with ACSL4/PTGS2. Both genes were significantly upregulated in the UC clinical samples.
conclusionACSL4 and PTGS2 are lipid metabolism- and ferroptosis-related biomarkers of UC, laying a foundation for clinical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.